Ketamine Versus Neostigmine in Ultrasound-Guided Transversus Abdominis Plane Block in Caesarean Section

NCT06871033 on ClinicalTrials.gov Phase 3 Alexandria University (academic or other) Started 2024-01-01 Completed

Riskier than 6% of active trials

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2025-01-01, after 2024-01-01 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-01-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: painstatusneuropathyor chronicsyndrome
Phrases that lowered it: undergoingpostoperativeelectiveasaphysical
Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
Accepts healthy volunteers: No (raises risk) · Who can join
Phase: 3 (lowers risk) · Design
Has a data monitoring committee: Yes (raises risk) · Design
Disease area, cancer: No (lowers risk) · Disease area
Trials the sponsor started in the prior 2 years: 176 (lowers risk) · Sponsor's track record
Sponsor type: academic or other (raises risk) · Sponsor's track record
Drug's FAERS reports with a death: 13.0% (lowers risk) · Drug's FDA history
Blinding: quadruple (lowers risk) · Design
Design: parallel (raises risk) · Design
Primary purpose: treatment (raises risk) · Design
Sponsor's past trials: 185 (lowers risk) · Sponsor's track record
Drug's FAERS reports marked serious: 91.7% (raises risk) · Drug's FDA history
Number of arms: 2 (raises risk) · Design
Maximum age: not given (raises risk) · Who can join
Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 3 (typical: 2)
Number of arms: 2
Allocation: randomized
Design: parallel
Primary purpose: treatment
Blinding: quadruple (typical: none)
Has a data monitoring committee: Yes (typical: 56% yes)
Responsible party: sponsor
Collaborators: 0
Keywords listed: 5 (typical: 1)

Who can join

Minimum age: not given (typical: 18)
Maximum age: not given (typical: 71)
Sex: all
Accepts healthy volunteers: No (typical: 9% yes)

Sponsor's track record

Sponsor type: academic or other
Sponsor's past trials: 185 (typical: 32)
Sponsor's past termination rate: 0% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 176 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 2 (typical: 1)
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 10998 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 1922 (typical: 412.5)
Drug's FAERS reports marked serious: 91.7% (typical: 85.6%)
Drug's FAERS reports with a death: 13.0% (typical: 15.9%)

Disease area and drugs

Disease areas: none of the 14 tracked areas
Drugs matched to FDA substances: ketamine, neostigmine

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

MgSO4 as Adjuvants to Bupivacaine vs Neostigmine in TAP Block in Cesarean Section NCT06513013 · started 2023 · scored riskier than 7% of active trials completed
Transversus Abdominis Plane Block in the Management of Acute Postoperative Pain Syndrome After Caesarean Section NCT02728323 · started 2013 · scored riskier than 8% of active trials terminated
THIS STUDY AIMS TO COMPARE TWO DRUGS KETAMINE AND TRAMAL IN PREVENTION OF SHIVERING IN PATIENTS UNDERGOING SPINAL ANESTHESIA STUDY POPULATION IS PT UNDERGOING C SECTION . DOSE OF KETAMINE IS 0.25mg/kg and That of TRAMAL 0.5mg/kg. NCT07784556 · started 2024 · scored riskier than 8% of active trials completed
Dexmedetomidine vs Ketamine as Adjuvants to Bupivacaine in Transversus Abdominus Plane Block in Inguinal Hernioplasty NCT07194694 · started 2025 · scored riskier than 11% of active trials completed
TAP Block for Postoperative Pain Control NCT02652156 · started 2015 · scored riskier than 16% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.